文献速递真菌感染

新型抗真菌药fosmanogepix治疗念珠菌血症的临床安全性和疗效:2期试验结果

Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

这项全球多中心非对照2期试验评估fosmanogepix一线治疗非中性粒细胞减少成人念珠菌血症的安全性和疗效。改良意向治疗人群(mITT)中治疗成功率为80%(16/20),第30天生存率为85%(17/20),21例中10例(48%)转为口服治疗,未发生治疗相关严重不良事件或停药。

要点

  • mITT人群治疗结束时治疗成功率为80%(16/20)。
  • 第30天生存率为85%(17/20),3例死亡与fosmanogepix无关。
  • 21例中10例(48%)转为口服fosmanogepix,未发生治疗相关严重不良事件或停药。

核心结论

  • 这项单臂2期试验结果提示,fosmanogepix可能对非中性粒细胞减少的念珠菌血症患者(包括肾功能损害者)是一种安全、耐受良好且有效的治疗。

研究设计与样本

  • 全球、多中心、非对照研究,评估fosmanogepix一线治疗非中性粒细胞减少成人念珠菌血症的安全性和疗效。
  • 入组标准为研究入组前96小时内血培养念珠菌阳性且既往系统性抗真菌治疗不超过2天。
  • 受试者接受fosmanogepix治疗14天:第1天静脉注射1000 mg每日两次,随后维持静脉注射600 mg每日一次,第4天起可选转为口服700 mg每日一次。
  • 改良意向治疗(mITT)人群为至少接受一剂fosmanogepix且确诊念珠菌血症(治疗开始后96小时内)的合格受试者。

主要发现

  • mITT人群中治疗结束时治疗成功率为80%(16/20)。
  • 第30天生存率为85%(17/20),3例死亡与fosmanogepix无关。
  • 21例中10例(48%)转为口服fosmanogepix。
  • fosmanogepix耐受良好,未发生治疗相关严重不良事件或停药。
  • fosmanogepix对基线念珠菌分离株具有强效体外活性(MIC范围:CLSI,0.002-0.03 mg/L)。

关键数值与推荐

  • 主要疗效终点为研究治疗结束时(EOST)由数据审查委员会判定的治疗成功,定义为血培养念珠菌清除、无需额外抗真菌治疗且EOST时存活。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fosmanogepix is a first-in-class antifungal targeting the fungal enzyme Gwt1, with broad-spectrum activity against yeasts and moulds, including multidrug-resistant fungi, formulated for intravenous (IV) and oral administration. METHODS: This global, multicenter, non-comparative study evaluated the safety and efficacy of fosmanogepix for first-line treatment of candidaemia in non-neutropenic adults. Participants with candidaemia, defined as a positive blood culture for Candida spp. within 96 h prior to study entry, with ≤2 days of prior systemic antifungals, were eligible. Participants received fosmanogepix for 14 days: 1000 mg IV twice daily on Day 1, followed by maintenance 600 mg IV once daily, and optional switch to 700 mg orally once daily from Day 4. Eligible participants who received at least one dose of fosmanogepix and had confirmed diagnosis of candidaemia (<96 h of treatment start) composed the modified intent-to-treat (mITT) population. Primary efficacy endpoint was treatment success at the end of study treatment (EOST) as determined by the Data Review Committee. Success was defined as clearance of Candida from blood cultures with no additional antifungal treatment and survival at the EOST. RESULTS: Treatment success was 80% (16/20, mITT; EOST) and Day 30 survival was 85% (17/20; 3 deaths unrelated to fosmanogepix). Ten of 21 (48%) were switched to oral fosmanogepix. Fosmanogepix was well tolerated with no treatment-related serious adverse events/discontinuations. Fosmanogepix had potent in vitro activity against baseline isolates of Candida spp. (MICrange: CLSI, 0.002-0.03 mg/L). CONCLUSIONS: Results from this single-arm Phase 2 trial suggest that fosmanogepix may be a safe, well-tolerated, and efficacious treatment for non-neutropenic patients with candidaemia, including those with renal impairment.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Pappas PG, Vazquez JA, Oren I, et al. Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial. J Antimicrob Chemother. 2023. PMID: 37596890. doi:10.1093/jac/dkad256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。